NightHawk Biosciences, Inc.
NHWK
NightHawk Biosciences, Inc. operates as an integrated biopharmaceutical firm,... NightHawk Biosciences, Inc. operates as an integrated biopharmaceutical firm, dedicated to advancing immune therapies and vaccines. Their core mission involves leveraging and modifying the body's immune system to combat a range of illnesses, particularly various cancers and infectious diseases. Central to their strategy is the proprietary gp96 platform. This platform encompasses two key technologies: ImPACT, an allogeneic (off-the-shelf) cell-based system designed to activate and expand T-cells, acting as a broad immune stimulant; and ComPACT, which combines antigen-specific T-cell activation with targeted co-stimulation in a single product. NightHawk's clinical pipeline features several promising candidates: HS-110, which has completed enrollment for its Phase II clinical trial, targeting advanced non-small cell lung cancer; and HS-130, currently undergoing a Phase I clinical trial for advanced solid tumors. Additionally, PTX-35, a novel T-cell co-stimulator agonist antibody that specifically targets DR3/TNFRSF25, is also in Phase I development. The company is also exploring DR3/TNFRSF25 as a general target for various immunotherapy applications. Beyond these, a COVID-19 vaccine is currently in preclinical stages. A notable collaboration involves Dr. James Shapiro at the University of Alberta, focusing on the manufacturing of a surrogate mouse version of PTX-35. Originally established as Heat Biologics, Inc. in 2008, the company rebranded to NightHawk Biosciences, Inc. in May 2022. Its headquarters are located in Morrisville, North Carolina.
